PharmaIndustrial India Magazine September-October 2023

Novotech Bags Consecutive Frost & Sullivan CRO Company of the Year Award Novotech has been selected as the CRO Company of the Year 2023 by growth advisory and opportunity analytics firm Frost & Sullivan. The company has been a recipient of the Frost & Sullivan Best Practices awards since 2006. Novotech’s Vice President, Clinical Ser- vices Dr. Yooni Kim will accept the award on behalf of Novotech at the award cer- emony on November 8, 2023 in Kuala Lumpur, Malaysia. David Frigstad, Chairman, Frost & Sul- livan said, “Novotech is at the forefront of innovation and growth and has con- solidated their leadership position by innovating and creating new solutions and services that meet ever-evolving customer needs.” Dr. John Moller, CEO of Novotech, ex- pressed his gratitude for this recognition, attributing the company’s success to its dedicated global team of clinical trial ex- perts. “To be consistently recognised for CRO excellence by leading industry an- alyst organization Frost & Sullivan further demonstrates our position in the sector as a trusted partner for biopharma,” said Dr. Moller. Frost & Sullivan Best Practices Re- search Analyst Azza Fazar commend- ed Novotech’s visionary approach to growth strategies, noting its adeptness in addressing emerging challenges and opportunities. She emphasized that Novotech’s comprehensive, value chain-centric approach to clinical devel- opment support, covering all phases of trials and offering customized services across diverse therapeutic areas, has garnered the trust of numerous biotech- nology clients worldwide. “Against this backdrop, Frost & Sullivan recognizes Novotech as CRO Company of the Year 2023,” she said. Fazar added, “The company stream- lines its processes and procedures to eliminate unnecessary bureaucracy, re- porting standard operating procedure reductions of 40 percent. Novotech’s dedication to customer satisfaction is evident in its client interactions, as indi- cated by an average engagement rating of 4.7 out of 5 in recent surveys.” “The company’s comprehensive 360-de- gree approach to clinical development support, covering all phases of trials and offering tailored services across ther- apeutic areas, has earned the trust of hundreds of biotechnology clients glob- ally,” she stated. Novotech has more than 3,000 employ- ees operating across 25 geographies with 34 office locations, including Great - er China, South Korea, Australia, New Zealand, the US, and Europe. The CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for de- livering high-quality expedited clinical trials. Recognized for its industry-leading con- tributions, Novotech has received nu- merous prestigious awards, including the CRO Leadership Award 2023 and the Best Cell & Gene Therapy CRO 2022 and 2023 awards. Additionally, the com- pany was honoured with the Frost & Sul- livan Asia-Pacific Contract Research Or - ganization Company of the Year Award in 2022 and 2023. Its commitment to collaboration is evident in the 50 Lead- ing Site Partnership agreements it has signed over the past three years. PHARMA INDUSTRIALINDIA · SEP-OCT 23 21 AWARDS AND ACCREDITATIONS